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The mechanisms that predispose to hypertension, cor-
onary artery disease (CAD), and type 2 diabetes (T2D) in
individuals of normal weight are poorly understood. In
contrast, in monogenic primary lipodystrophy—a reduc-
tion in subcutaneous adipose tissue—it is clear that it is
adipose dysfunction that causes severe insulin resis-
tance (IR), hypertension, CAD, and T2D. We aimed to test
the hypothesis that common alleles associated with IR
also inﬂuence the wider clinical and biochemical proﬁle
of monogenic IR. We selected 19 common genetic var-
iants associated with fasting insulin–based measures
of IR. We used hierarchical clustering and results from
genome-wide association studies of eight nondisease
outcomes of monogenic IR to group these variants. We
analyzed genetic risk scores against disease outcomes,
including 12,171 T2D cases, 40,365 CAD cases, and
69,828 individuals with blood pressure measurements.
Hierarchical clustering identiﬁed 11 variants associated
with a metabolic proﬁle consistent with a common, sub-
tle form of lipodystrophy. A genetic risk score consisting
of these 11 IR risk alleles was associated with higher
triglycerides (b = 0.018; P = 4 3 10229), lower HDL
cholesterol (b = 20.020; P = 7 3 10237), greater hepatic
steatosis (b = 0.021; P = 3 3 1024), higher alanine trans-
aminase (b = 0.002; P = 3 3 1025), lower sex-hormone-
binding globulin (b = 20.010; P = 9 3 10213), and lower
adiponectin (b = 20.015; P = 2 3 10226). The same risk
alleles were associated with lower BMI (per-allele b =
20.008; P = 7 3 1028) and increased visceral-to-
subcutaneous adipose tissue ratio (b = 20.015; P = 6 3
1027). Individuals carrying ‡17 fasting insulin–raising
alleles (5.5% population) were slimmer (0.30 kg/m2) but
at increased risk of T2D (odds ratio [OR] 1.46; per-allele
P = 5 3 10213 ), CAD (OR 1.12; per-allele P = 1 3 1025),
and increased blood pressure (systolic and diastolic
blood pressure of 1.21 mmHg [per-allele P = 2 3 1025]
and 0.67 mmHg [per-allele P = 2 3 1024], respectively)
compared with individuals carrying £9 risk alleles (5.5%
population). Our results provide genetic evidence for
a link between the three diseases of the “metabolic syn-
drome” and point to reduced subcutaneous adiposity as
a central mechanism.
Some individuals are at increased risk of metabolic
diseases, including hypertension, coronary artery disease
(CAD), and type 2 diabetes (T2D) despite a normal BMI.
These individuals are often referred to as “metabolically
obese, normal weight” (1,2). The mechanisms that cause
an adverse metabolic phenotype in individuals of normal
weight are poorly understood. One possible mediator is
insulin resistance (IR), which was proposed 25 years ago
as a potential link among hypertension, CAD, and T2D
and which led to the idea of a “metabolic syndrome” (3).
Three broad categories of unusually severe IR exist
caused by mutations in single genes. The mechanisms
underlying these monogenic disorders are better under-
stood (4) compared with the “common” IR for which
genome-wide association studies (GWAS) have identiﬁed
numerous associated alleles. The ﬁrst category is lipodys-
trophy, a partial or complete lack of subcutaneous fat,
most often caused by mutations in genes involved in fat
cell differentiation or function (e.g., PPARG [5]) or, rarely,
by more distal insulin signaling defects (AKT2 [6]). Lipo-
dystrophy is characterized by varying degrees of adipose
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tissue deﬁciency, severe dyslipidemia (high triglycerides,
low HDL cholesterol [HDL-C]), severe fatty liver, low adi-
ponectin, low sex-hormone-binding globulin (SHBG), and
an increased risk of hypertension, CAD, and T2D (7–9).
The uncoupling of indices of adiposity from severe meta-
bolic disease in lipodystrophy is one of the key pieces of
evidence for the notion that expandable, metabolically ﬂex-
ible adipose tissue is essential for health (9). The second
category includes syndromes (such as those caused by lep-
tin deﬁciency) in which IR is driven by a primary effect on
energy homeostasis, leading to severe obesity and a bio-
chemical proﬁle resembling the “common” metabolic syn-
drome. These disorders are usually characterized by
hyperphagia from an early age and extreme childhood
obesity and are most commonly attributable to mutations
affecting key components of hypothalamic neurocircuitry
(10). The third category includes syndromes caused by
loss-of-function mutations in the insulin receptor called
“receptoropathies.” These disorders are characterized by
extremely high insulin levels but lack dyslipidemia and
fatty liver disease and often exhibit normal or raised lev-
els of plasma adiponectin and SHBG (11), quite unlike
common IR.
In this study, we tested the hypothesis that common
alleles associated with IR inﬂuence the metabolic outcomes
of monogenic forms of IR, including increased risk of hy-
pertension, CAD, and T2D. We aimed to use the subclinical
phenotypes that characterize different forms of monogenic IR
to determine whether mechanistically informative subpheno-
types of common IR may be identiﬁed. Recent GWAS have
identiﬁed 19 common genetic variants associated with indices
of IR based on fasting plasma insulin concentration (12,13).
One of these variants is in the FTO gene, and the allele asso-
ciated with greater risk of IR is associated with higher BMI
and an adverse metabolic proﬁle (12). This pattern is closely
similar to that of severe obesity. A second common variant,
near the IRS1 gene, is associated with IR, lower total body fat
content, lower subcutaneous fat amount, dyslipidemia, lower
adiponectin, and increased risk of diabetes and CAD (14). This
pattern is closely similar to that of “lipodystrophic” IR, but
quite unlike the severe obesity or “receptoropathy” patterns.
We show that a cluster of 11 variants among 19 common
genetic variants associated with indices of IR are collectively
associated with metabolic features similar to those of lipodys-
trophy, including a lower BMI, higher visceral-to-subcutaneous
adipose tissue ratio, and a predisposition to T2D, hyperten-
sion, and CAD. This ﬁnding provides genetic evidence for an
association between reduced subcutaneous adiposity and BMI
and increased risk of “obesity-associated” diseases.
RESEARCH DESIGN AND METHODS
Selection of Genetic Variants
We selected the 19 independent single nucleotide poly-
morphisms associated with fasting insulin as reported in
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the most recent Meta-Analysis of Glucose and Insulin
Consortium (MAGIC) GWAS (12) (Supplementary Table
1). Of these 19 variants, 14 were detected at genome-wide
signiﬁcance before correction for BMI, and 5 only reached
signiﬁcance after correcting for BMI. All were at least
nominally associated with uncorrected fasting insulin at
P , 1.19 3 1025. Although not the optimum measure of
IR, collectively these variants are associated with gold
standard measures of IR (15). For comparison, we se-
lected the 32 variants associated with BMI from the Ge-
netic Investigation of ANthropometric Traits (GIANT)
consortium (16) (Supplementary Table 2).
Metabolic Traits
We used summary statistics data from publicly available
GWAS (Table 1).
Study Design
Selection of Nondisease Metabolic Traits
We selected eight traits known to be nondisease markers
of the three different subtypes of monogenic IR (Table 1).
These traits were HDL-C (17) and triglyceride levels (17)
to represent dyslipidemia; BMI (16) and visceral-to-
subcutaneous adipose tissue ratio (18) to represent
adiposity; computed tomography (CT)-measured hepatic
steatosis (19) and plasma levels of the liver enzyme
alanine transaminase (ALT) (20) to represent the spec-
trum of nonalcoholic fatty liver disease; and circulating
levels of the fat cell–derived protein adiponectin (21)
and circulating levels of the liver-derived protein
SHBG (22).
Selection of Metabolic Disease Outcome
We selected six metabolic diseases or disease-related out-
comes known to be increased in some forms of monogenic
IR. These outcome traits represent the diseases that the
metabolic syndrome tries to predict: carotid intima-media
thickness (cIMT) and carotid plaque as surrogates of
atherosclerosis (23); diastolic and systolic blood pressure
to represent hypertension (24); and CAD (25) and T2D
(26). Further details of disease outcomes are available in
Supplementary Table 3.
Cluster Analysis of Fasting Insulin–Associated Genetic
Variants Using Nondisease Metabolic Traits
We used a hierarchical clustering analysis and the eight
nondisease traits to group fasting insulin variants into
those likely to predispose to IR through similar mecha-
nisms. This method is used for clustering gene expression
proﬁles to discover coregulated and functionally related
genes or to identify subtypes of related samples (27) and
is similar to principal components analyses. This approach
was recently used to group 37 genetic variants associated
with T2D into those with primary effects on glucose sens-
ing, b-cell dysfunction, or IR (28). We used the summary
statistics of the 19 fasting insulin variants (12) from the
GWAS of the 8 nondisease metabolic traits (Table 1) and
aligned all effects to the fasting insulin increasing alleles.
We used the “pvclust” package in R, which performs ag-
glomerative hierarchical clustering and bootstrapping, to
estimate the stability and signiﬁcance of the resulting
clusters (29). In this method, variants are assigned to
clusters based on associations with a similar set of phe-
notypes. We used Euclidean metrics in the algorithm to
calculate pairwise distance between the effect sizes on
biomarker levels of the variants as input data. We used
“ward” as a cluster method. The P values in this method
represent the relative frequency of how often the variants
are in the same cluster.
Table 1—Source of summary statistic data from GWAS of metabolic traits and their changes in monogenic forms of IR
Trait Consortia
Maximum N
(all or cases
vs. controls) Reference
Monogenic
obesity*
Monogenic
lipodystrophy*
Monogenic
receptoropathy*
Nondisease metabolic traits
SHBG CHARGE 21,000 (22) – – 0/+
HDL-C GLGC 99,900 (17) – – 0
Adiponectin ADIPOGEN 29,346 (21) – – 0/+
BMI GIANT 123,865 (16) + – 0
VATSAT ratio VATGen 10,557 (18) + + 0
CT-measured
hepatic steatosis GOLD 7,176 (19) + + 0
ALT — 55,474 (20) + + 0
Triglyceride GLGC 96,598 (17) + + 0
Metabolic disease and
disease-related outcomes
T2D DIAGRAM 12,171 vs. 56,862 (26) + + +
CAD CARDIoGRAM 40,365 vs. 63,714 (25) + + 0
Systolic blood pressure ICBP 69,828 (24) + + 0
Diastolic blood pressure ICBP 69,816 (24) + + 0
cIMT CHARGE 31,210 (23) + + 0
Carotid plaque CHARGE 25,179 (23) + + 0
VATSAT, visceral-to-subcutaneous adipose tissue. *+ refers to high in condition, – refers to low in condition, and 0 refers to not
changed.
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Meta-analysis of Fasting Insulin– and BMI-Associated
Genetic Variants Against Nondisease Metabolic Traits
and Metabolic Disease Outcomes
We calculated genetic risk scores of variants that clustered
together by meta-analyzing summary statistics of genotype-
phenotype associations across the variants for a given
trait. This method has been described and validated
previously (30). We repeated this analysis for the 32 var-
iants known to be associated with BMI. We compared per-
allele effects of fasting insulin clusters to each other and
to per-allele effects of the BMI variants using Z test. We
considered a conservative nominal P # 0.001 as signiﬁ-
cant, corresponding to a Bonferroni correction of 42 tests
(14 traits tested [8 nondisease metabolic traits and 6
metabolic disease outcomes] against 3 clusters).
Sensitivity Analyses
We performed three sets of sensitivity analyses to test
whether weighting changes the association of each genetic
risk score with nondisease marker and disease outcome
traits. We calculated the genetic risk score using summary
statistics of genotype-phenotype associations weighted in
three different ways: 1) by each variant’s corresponding
effect size with the primary trait (fasting insulin) as
weight; 2) by each variant’s corresponding effect size
with the primary trait (fasting insulin) using the formula
used before (21),
betariskallelescore ¼
∑
k
i¼1
wibisi
2 2
∑
k
i¼1
wi2si2 2
seðbetariskallelescoreÞ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
∑
k
i¼1
wi2si2 2
vuuut ;
where bi refers to the effect of varianti on the outcome
data, si is the associated SE estimate, and wi is the effect
of varianti on fasting insulin; and 3) by weighting variants
and taking into account allele frequencies,
wi ¼ 2 ∗EAFi ∗NEAFi ∗bi2
where EAFi is the effect allele frequency of the varianti
and NEAFi is the frequency of the other allele for varianti.
RESULTS
A Cluster of 11 Fasting Insulin–Associated Genetic
Variants Resembles the Metabolic Proﬁle of
Monogenic Lipodystrophic IR
Using the 8 nondisease metabolic traits of monogenic IR
and all 19 common fasting insulin associated genetic variants
(12), we identiﬁed 11 genetic variants that together could be
distinguished statistically from the remaining 8 variants (P of
the robustness of the branching event = 96%) (Fig. 1). This
cluster of 11 common variants included those in or near
the genes IRS1, GRB14, ARL15, FAM13A, LYPLAL1, PEPD,
PDGFC, RSPO3, PPARG, TET2, and ANKRD55. The 11-
variant genetic risk score was associated with all 8 non-
disease markers of monogenic IR. As expected, given the
traits used to deﬁne the cluster, fasting insulin–raising
alleles were associated with higher triglycerides (b =
0.018; P = 4 3 10229), lower HDL-C (b = 20.020; P =
7 3 10237), greater hepatic steatosis (b = 0.021; P = 3 3
1024) higher ALT (b = 0.002; P = 3 3 1025), lower SHBG
(b = 20.010; P = 9 3 10213), and lower adiponectin (b =
20.015; P = 2 3 10226). In contrast to this adverse
metabolic proﬁle, the fasting insulin–raising alleles were
associated with lower BMI (per-allele b = 20.008; P = 7 3
1028) (Table 2). The fasting insulin–raising alleles were
also associated with increased visceral-to-subcutaneous
adipose tissue ratio (b = 20.015; P = 6 3 1027) (Table 2).
The association with visceral-to-subcutaneous adipose tissue
ratio was primarily driven by reduced subcutaneous adipose
tissue (20.014; 2 3 1026). As an example, these effects
meant that the 5.5% of individuals carrying $17 fasting
insulin–raising alleles were 0.30 kg/m2 of BMI slimmer
but had triglyceride levels 0.16 SD units higher and HDL
levels 0.18 SD units lower, compared with the 5.5% of indi-
viduals carrying #9 fasting insulin–raising alleles. Note that
the units for each biomarker may be different depending on
the source of GWAS data (Table 2).
A second cluster of ﬁve genetic variants (P of the ro-
bustness of the branching event = 98%) included those in
or near the genes YSK4, UKRF1BP1, TCF7L2, IGF1, and
HIP1 (Fig. 1) but was not associated with any of the non-
disease markers of monogenic IR (all P values . 0.001)
except higher BMI (b = 0.012; P = 3 3 1026) (Supple-
mentary Table 4) and so was not studied further. Variants
in or near FTO, GCKR, and PPP1R3B did not cluster with
other variants, most likely because of their primary effects
on BMI, triglycerides, and HDL-C, respectively (Fig. 1;
Supplementary Table 4). The variant in FTO provides
a proof-of-principle example of how a BMI-associated
variant can be separated from variants associated with
fasting insulin through mechanisms other than higher
BMI. The GCKR variant shows how the use of multiple
metabolic phenotypes can be used to separate out differ-
ent mechanisms—we know this variant is likely to oper-
ate through a particular mechanism linking glucose to
lipid metabolism (31) in the liver and it was individually
associated with multiple liver-based phenotypes (Supple-
mentary Table 4).
A Cluster of 11 Fasting Insulin Associated Variants
Resembling Lipodystrophy Is Associated With
Metabolic Disease Outcomes
The genetic risk score consisting of the 11 fasting insulin
variants was associated with 4 of the 6 metabolic disease
outcomes, in directions consistent with the lipodystrophy-
like phenotype. The 11-variant genetic risk score was
associated with a higher risk of T2D (per-allele odds ratio
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[OR] = 1.043; 95% CIs 1.031, 1.055; P = 5 3 10213) and
CAD (per-allele OR = 1.013; 95% CIs 1.007, 1.019; P =
1 3 1025), and higher systolic (b = 0.135; 95% CIs 0.072,
0.198; P = 2 3 1025) and diastolic blood pressure (b =
0.075; 95% CIs 0.036, 0.114; P = 2 3 1024) but was not as-
sociated with cIMT or risk of carotid plaques (P values .
0.001) (Fig. 2; Table 2). As an example, these effects
meant that individuals carrying $17 fasting insulin–
raising alleles (5.5% of the population) were 0.30 kg/m2
slimmer but had an estimated OR of T2D and coronary
heart disease of 1.46 and 1.12, respectively, and an esti-
mated increase in systolic and diastolic blood pressure of
1.21 and 0.67 mmHg, respectively, compared with indi-
viduals carrying#9 fasting insulin–raising alleles (5.5% of
the population) (Supplementary Fig. 1A and C). Sensitiv-
ity analyses using three different methods to weight
individual variants provided very similar results
(Supplementary Table 5), and exclusion of the previously
Figure 1—Cluster analysis of fasting insulin variants using eight traits known to be nondisease metabolic traits of monogenic IR, including
those representing dyslipidemia (HDL and triglyceride), adiposity (BMI and visceral-to-subcutaneous adipose tissue ratio), fatty liver (CT-
measured hepatic steatosis and the liver enzyme ALT), and adiponectin and SHBG levels. The dendrogram (A) shows that 11 variants and 5
variants are grouped in two signiﬁcant clusters (the approximate unbiased values = 96% [P = 0.04] and 98% [P = 0.02], respectively). The
heatmap (B) shows this cluster is consistent with monogenic lipodystrophic IR; the stronger the green color, the stronger the effect of the
insulin-raising allele with reduced trait levels; the stronger the pink color, the stronger the effect of the insulin-raising allele with higher trait
levels. VATSAT, visceral-to-subcutaneous adipose tissue ratio; NAFLD, nonalcoholic fatty liver disease.
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reported variant near IRS1 did not appreciably change the
results (Supplementary Table 6).
Comparing the Cluster of 11 Fasting Insulin Variants
Resembling Lipodystrophy to the 32 Known BMI
Variants
We next compared the per-allele effects of the cluster of
fasting insulin–associated variants with the per-allele
effects of the known 32 BMI variants. They were both
associated with nondisease metabolic traits, with two no-
table differences. 1) The cluster of 11 fasting insulin var-
iants was associated with higher visceral-to-subcutaneous
adipose tissue ratio, whereas the 32-variant BMI group
was associated with lower visceral-to-subcutaneous adipose
tissue ratio (Supplementary Table 4). 2) The 32-variant
BMI cluster was not associated with CT-measured hepatic
steatosis (Supplementary Table 4). Compared with the 32-
BMI-variant risk score, the 11 variant fasting insulin clus-
ter was more strongly associated with risk of T2D (BMI
per-allele OR = 1.021 [1.016–1.028], P = 1 3 10212; the
11-variant cluster per-allele OR = 1.043 [1.031–1.055],
P = 5 3 10213; P of difference = 0.002) but did not
have detectably different per-allele associations with CAD
(Supplementary Fig. 1B and D; Supplementary Table 4). As
with the fasting insulin cluster, the 32-BMI-variant score
was not associated with cIMT or carotid plaque.
DISCUSSION
We have shown that common alleles associated with IR
(as measured by fasting insulin) are associated with
metabolic outcomes of monogenic forms of IR. Most
notably, a cluster of 11 common genetic variants show
a pattern of metabolic trait associations consistent with
a common, subtle “lipodystrophy-like” phenotype, confer-
ring an increased risk of hypertension, T2D, and CAD
despite a lower BMI. Our ﬁndings are consistent with
“adipose expandability” hypotheses (32), which propose
that the expandability of adipose tissue is limited and
that it is the exceeding of this intrinsic storage capacity,
which is partly genetically determined, which contributes
to common forms of IR. More broadly, our results suggest
that there is a partly genetic basis to the widely reported
“metabolically obese, normal-weight” phenotype (1,2).
Our study has a number of implications. First, our
results provide evidence that the 11 variants associated
with a lipodystrophy-like metabolic phenotype exert their
effect through a primary role in adipose tissue. Consistent
with this notion, the genetic loci involved include PPARG,
which is the most important transcription factor in the
control of adipogenesis (33,34) and which harbors dominant
negative mutations in a Mendelian subtype of partial lipo-
dystrophy featuring reduced body fat and severely dys-
lipidemic IR (35). Thus, although our ﬁndings do not prove
causality in the observed associations, they indicate that
future in vitro and in vivo functional studies could start
with adipose tissue–based hypotheses and the genes located
near the 11 variants highlighted by our cluster analysis.
Second, we have shown that using phenotypic features
of monogenic diseases may be an informative method to
help understand likely mechanisms of more common, less
penetrant alleles. We show that common fasting insulin–
associated variants identiﬁed by GWAS may be clustered
into discrete subgroups using a panel of nondisease
markers that discriminate different forms of monogenic
severe IR (9). These markers included circulating factors
such as lipids, adiponectin, and SHBG as well as adiposity.
The approach is analogous to that recently used to cluster
T2D variants into different groups according to subclini-
cal phenotypes (28).
Third, our results raise the possibility that individuals
carrying large numbers of fasting insulin–raising alleles at
these 11 loci represent human “in vivo” models of adipose
tissue dysfunction. Although individually the common alleles
Table 2—Results of genotype risk score analysis of the 11 “lipodystrophy-like” variants
Category/trait Unit Per-allele b 95% CI P N
Nondisease metabolic traits of monogenic IR
SHBG (BMI adjusted) Natural log 20.010 20.012, 20.008 9 3 10213 21,000
HDL-C SD 20.020 20.024, 20.016 7 3 10237 99,900
Adiponectin (BMI adjusted) log 20.015 20.017, 20.013 2 3 10226 29,346
BMI SD 20.008 20.012, 20.004 7 3 1028 123,865
VATSAT ratio z-score 0.015 0.009, 0.021 6 3 1027 10,557
CT-measured hepatic steatosis SD 0.021 0.009, 0.033 3 3 1024 7,176
ALT log10 0.002 0.001, 0.003 3 3 10
25 55,474
Triglyceride SD 0.018 0.014, 0.022 4 3 10229 96,598
Metabolic disease and disease-related outcomes
T2D OR 1.043 1.031, 1.055 5 3 10213 12,171 vs. 56,862
CAD OR 1.013 1.007, 1.019 1 3 1025 40,365 vs. 63,714
Systolic blood pressure (BMI adjusted) mmHg 0.135 0.072, 0.198 2 3 1025 69,828
Diastolic blood pressure (BMI adjusted) mmHg 0.075 0.036, 0.114 2 3 1024 69,816
cIMT log 0.000 20.002, 0.002 0.70 31,210
Carotid plaques OR 1.005 0.991, 1.019 0.50 25,179
The 8 nondisease metabolic traits were used to select the 11 variants, so associations are not independent of the clustering process.
The metabolic disease outcomes were not used in the clustering process and so represent independent tests. VATSAT, visceral-to-
subcutaneous adipose tissue. P values # 0.001 are in bold.
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have very subtle effects, ;5.5% of people in the general
population will have an ;1.46 increased odds of T2D and
1.12 increased odds of CAD compared with people from the
other end of the distribution of these alleles, but these
people will have lower BMIs. More in depth studies of the
fat distribution and adipose tissue morphology and function
Figure 2—Forest plots of the effect of the 11 “lipodystrophy-like” variants on six metabolic disease outcomes. The x-axis is the effect size
per fasting insulin–increasing alleles on each trait. The dashed line is the null effect. For cIMT, actual effects ranged from 20.003 to 0.003
but here are shown rounded to two decimal places. FE, ﬁxed effect.
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of these individuals may lead to further understanding of
the BMI-independent mechanisms of metabolic disease.
Finally, if more lipodystrophy-like variants are identi-
ﬁed through ongoing genetic studies, testing such var-
iants in combination may have clinical utility in identifying
individuals at high genetic risk of “adipose failure.” These
individuals have previously been termed the metabolically
obese, normal weight (1,2). In such people, it may be ap-
propriate to use lower BMI-based thresholds for access to
adipose ofﬂoading therapies, including oral weight loss
medications and bariatric surgery, as they have the poten-
tial to develop metabolic disease at a lower BMI.
Our study has some notable strengths and some
limitations. The main strength is that we used a genetic
approach to dissect the associations between multiple
metabolic traits. While we cannot be certain of the primary
trait involved, genetic variants are far less susceptible to
confounding and bias than most nongenetic measures, and
so our results provide strong support for a causal link
between the traits tested. The second main strength is that
we used a wider panel of phenotypic features than IR alone
as a basis for subgrouping fasting insulin–associated var-
iants while, critically, constraining this panel to those
markers that have shown utility in discriminating different
forms of monogenic IR.
There are some important limitations to our results.
Firstly and most importantly, the associations we observed,
while statistically very robust, are very subtle in terms of
effects on metabolic traits. More than 50,000 individuals
were required to identify the variants associated with
fasting insulin, and so they explain only a small proportion
of the variation in IR and the other metabolic traits we have
examined. Hence our results do not provide evidence that
the “polygenic lipodystrophy-like” phenotype is the primary
mechanism of IR and its link to metabolic disease but in-
stead establish the principle that reduced adipose expand-
ability is one mechanism that links these traits in the
general population. Further genetic discoveries will help
us understand the relative role of this mechanism. A second
limitation was that our hierarchical clustering approach was
based on eight nondisease markers that are correlated with
each other, and many of the same studies and individuals
contributed to multiple phenotypes. Further studies with
individual level data will be needed to able to account for
these correlations. However, using two correlated, but not
perfectly correlated measures, such as adiponectin and
SHBG, will increase the resolution of the clustering ap-
proach, as recently demonstrated in a similar approach to
cluster T2D variants by correlated glycemic traits. A third
limitation is that the fasting insulin–associated variants
were ascertained from truncated distributions of glycemic
traits because the MAGIC study excluded individuals with
fasting glucose above 7.0 mmol/L to limit the possibility of
confounding effects from diabetes disease processes and
treatments. This ascertainment issue may explain why
the diabetes risk allele at TCF7L2 and possibly other
alleles may be associated with apparently greater insulin
sensitivity—carriers of T2D risk alleles will need to be sub-
tly more insulin sensitive to remain nondiabetic, for exam-
ple. It is therefore reassuring that TCF7L2 does not cluster
with the 11 “lipodystrophy-like” variants. A fourth main
limitation is that some of the phenotypes used were not
gold standard measures. We used genetic variants associated
with fasting insulin, which is not the best measure of IR, but
we note that the genetic risk score we used is strongly
associated with more direct measures of IR in the accompa-
nying article (15). We also used cIMT and carotid plaque as
surrogates for atherosclerosis, and it is well-known that
these traits are suboptimal measures of atherosclerosis
(23). The lack of association between the cluster of 11 fast-
ing insulin variants and cIMT or carotid plaque could be due
to reduced statistical power due to sample size or the intra-
individual variation and measurement error involved in
these phenotypes. Alternatively, the lack of association could
be because the fasting insulin–associated variants predispose
to CAD through pathways other than those captured by
cIMT and carotid plaque measures.
In summary, the group of genetic variants associated
with a “lipodystrophy-like” phenotype provides evidence
that subtle genetically inﬂuenced higher visceral-to-
subcutaneous adipose tissue ratio, fasting insulin, and
dyslipidemia in combination can increase the risk of
hypertension, CAD, and T2D in the absence of increased
BMI. Our results provide genetic evidence for a link be-
tween the three diseases of the “metabolic syndrome.”
Our results may help elucidate the mechanistic pathways
of how common genetic loci are linked to IR and the
mechanisms behind how some individuals can remain rel-
atively healthy despite obesity while others are susceptible
to heart disease and diabetes despite relative leanness.
Our results highlight the potential role of adipose
tissue dysfunction as one of the underlying mechanisms
for IR, hypertension, T2D, and CAD.
Acknowledgments. The authors are grateful to all GWAS consortia
who provided the lookups, including CHARGE, GLGC, ADIPOGEN, GIANT, VATGen,
GOLD, GLGC, DIAGRAM, CARDIoGRAM, and ICBP.
Funding. The authors thank the European Research Council (ERS: 323195),
Wellcome Trust, and University of Exeter Medical School. P.B.M. acknowledges
the National Institute for Health Research Barts Cardiovascular Biomedical
Research Unit for supporting this work.
Duality of Interest. No potential conﬂicts of interest relevant to this article
were reported.
Author Contributions. H.Y. conceived and designed the study, designed
the statistical analysis, analyzed the data, and wrote the ﬁrst draft of the manuscript.
R.A.S. provided data from published GWAS, commented on the manuscript, and
agreed with manuscript results and conclusions. C.C.W., W.Z., G.B.E., J.C.B., C.O.,
N.F., and Z.D. provided data from published GWAS and agreed with manuscript
results and conclusions. E.S. provided data from published GWAS, commented
on the manuscript, and agreed with manuscript results and conclusions. P.B.M.
provided data from published GWAS. P.B.M., C.S.F., M.-F.H., and J.B.R.
commented on the manuscript and agreed with manuscript results and
conclusions. M.W., I.B.B., J.W.K., L.Y.-A., J.R.B.P, J.C.C., J.S.K., and C.L. agreed
with manuscript results and conclusions. R.K.S. wrote the ﬁrst draft of the
manuscript and commented on the manuscript. T.M.F. conceived and designed
4376 Lower Subcutaneous Fat and IR—A Genetic Link Diabetes Volume 63, December 2014
the study and wrote the ﬁrst draft of the manuscript. T.M.F. is the guarantor of
this work and, as such, had full access to all the data in the study and takes
responsibility for the integrity of the data and the accuracy of the data analysis.
Prior Presentation. Parts of this study were presented as a poster at the
74th Scientiﬁc Sessions of the American Diabetes Association, San Francisco,
CA, 13–17 June 2014.
References
1. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically
obese, normal-weight individual revisited. Diabetes 1998;47:699–713
2. Ruderman NB, Schneider SH, Berchtold P. The “metabolically-obese,”
normal-weight individual. Am J Clin Nutr 1981;34:1617–1621
3. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human
disease. 1988. Nutrition 1997;13:65; discussion 64, 66
4. Semple RK, Savage DB, Cochran EK, Gorden P, O’Rahilly S. Genetic syn-
dromes of severe insulin resistance. Endocr Rev 2011;32:498–514
5. Semple RK, Chatterjee VK, O’Rahilly S. PPAR gamma and human metabolic
disease. J Clin Invest 2006;116:581–589
6. George S, Rochford JJ, Wolfrum C, et al. A family with severe insulin re-
sistance and diabetes due to a mutation in AKT2. Science 2004;304:1325–1328
7. Semple RK, Cochran EK, Soos MA, et al. Plasma adiponectin as a marker of
insulin receptor dysfunction: clinical utility in severe insulin resistance. Diabetes
Care 2008;31:977–979
8. Semple RK, Halberg NH, Burling K, et al. Paradoxical elevation of high-
molecular weight adiponectin in acquired extreme insulin resistance due to in-
sulin receptor antibodies. Diabetes 2007;56:1712–1717
9. Stears A, O’Rahilly S, Semple RK, Savage DB. Metabolic insights from
extreme human insulin resistance phenotypes. Best Pract Res Clin Endocrinol
Metab 2012;26:145–157
10. Bochukova EG, Huang N, Keogh J, et al. Large, rare chromosomal deletions
associated with severe early-onset obesity. Nature 2010;463:666–670
11. Semple RK, Soos MA, Luan J, et al. Elevated plasma adiponectin in humans
with genetically defective insulin receptors. J Clin Endocrinol Metab 2006;91:
3219–3223
12. Scott RA, Lagou V, Welch RP, et al.; DIAbetes Genetics Replication and
Meta-analysis (DIAGRAM) Consortium. Large-scale association analyses identify
new loci inﬂuencing glycemic traits and provide insight into the underlying bi-
ological pathways. Nat Genet 2012;44:991–1005
13. Manning AK, Hivert MF, Scott RA, et al.; DIAbetes Genetics Replication And
Meta-analysis (DIAGRAM) Consortium; Multiple Tissue Human Expression Re-
source (MUTHER) Consortium. A genome-wide approach accounting for body
mass index identiﬁes genetic variants inﬂuencing fasting glycemic traits and
insulin resistance. Nat Genet 2012;44:659–669
14. Kilpeläinen TO, Zillikens MC, Stancákova A, et al. Genetic variation near
IRS1 associates with reduced adiposity and an impaired metabolic proﬁle. Nat
Genet 2011;43:753–760
15. Scott RA, Fall T, Pasko D, et al. Common genetic variants highlight the role
of insulin resistance and body fat distribution in type 2 diabetes, independent of
obesity. Diabetes 2014;63:4378–4387
16. Speliotes EK, Willer CJ, Berndt SI, et al.; MAGIC; Procardis Consortium.
Association analyses of 249,796 individuals reveal 18 new loci associated with
body mass index. Nat Genet 2010;42:937–948
17. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and pop-
ulation relevance of 95 loci for blood lipids. Nature 2010;466:707–713
18. Fox CS, Liu Y, White CC, et al.; GIANT Consortium; MAGIC Consortium; GLGC
Consortium. Genome-wide association for abdominal subcutaneous and visceral
adipose reveals a novel locus for visceral fat in women. PLoS Genet 2012;8:
e1002695
19. Speliotes EK, Yerges-Armstrong LM, Wu J, et al.; NASH CRN; GIANT Con-
sortium; MAGIC Investigators; GOLD Consortium. Genome-wide association
analysis identiﬁes variants associated with nonalcoholic fatty liver disease that
have distinct effects on metabolic traits. PLoS Genet 2011;7:e1001324
20. Chambers JC, Zhang W, Sehmi J, et al.; Alcohol Genome-wide Association
(AlcGen) Consortium; Diabetes Genetics Replication and Meta-analyses
(DIAGRAM+) Study; Genetic Investigation of Anthropometric Traits (GIANT) Con-
sortium; Global Lipids Genetics Consortium; Genetics of Liver Disease (GOLD)
Consortium; International Consortium for Blood Pressure (ICBP-GWAS); Meta-
analyses of Glucose and Insulin-Related Traits Consortium (MAGIC). Genome-
wide association study identiﬁes loci inﬂuencing concentrations of liver enzymes
in plasma. Nat Genet 2011;43:1131–1138
21. Dastani Z, Hivert MF, Timpson N, et al.; DIAGRAM+ Consortium; MAGIC
Consortium; GLGC Investigators; MuTHER Consortium; DIAGRAM Consortium;
GIANT Consortium; Global B Pgen Consortium; Procardis Consortium; MAGIC
investigators; GLGC Consortium. Novel loci for adiponectin levels and their in-
ﬂuence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of
45,891 individuals. PLoS Genet 2012;8:e1002607
22. Coviello AD, Haring R, Wellons M, et al. A genome-wide association meta-
analysis of circulating sex hormone-binding globulin reveals multiple Loci im-
plicated in sex steroid hormone regulation. PLoS Genet 2012;8:e1002805
23. Bis JC, Kavousi M, Franceschini N, et al.; CARDIoGRAM Consortium. Meta-
analysis of genome-wide association studies from the CHARGE consortium
identiﬁes common variants associated with carotid intima media thickness and
plaque. Nat Genet 2011;43:940–947
24. Ehret GB, Munroe PB, Rice KM, et al.; International Consortium for Blood
Pressure Genome-Wide Association Studies; CARDIoGRAM consortium; CKDGen
Consortium; KidneyGen Consortium; EchoGen consortium; CHARGE-HF consor-
tium. Genetic variants in novel pathways inﬂuence blood pressure and cardio-
vascular disease risk. Nature 2011;478:103–109
25. Deloukas P, Kanoni S, Willenborg C, et al.; CARDIoGRAMplusC4D Consor-
tium; DIAGRAM Consortium; CARDIOGENICS Consortium; MuTHER Consortium;
Wellcome Trust Case Control Consortium. Large-scale association analysis
identiﬁes new risk loci for coronary artery disease. Nat Genet 2013;45:25–33
26. Morris AP, Voight BF, Teslovich TM, et al.; Wellcome Trust Case Control
Consortium; Meta-Analyses of Glucose and Insulin-related traits Consortium
(MAGIC) Investigators; Genetic Investigation of ANthropometric Traits (GIANT)
Consortium; Asian Genetic Epidemiology Network–Type 2 Diabetes (AGEN-T2D)
Consortium; South Asian Type 2 Diabetes (SAT2D) Consortium; DIAbetes Ge-
netics Replication And Meta-analysis (DIAGRAM) Consortium. Large-scale as-
sociation analysis provides insights into the genetic architecture and
pathophysiology of type 2 diabetes. Nat Genet 2012;44:981–990
27. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of
genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863–14868
28. Dimas AS, Lagou V, Barker A, et al.; MAGIC Investigators. Impact of type 2
diabetes susceptibility variants on quantitative glycemic traits reveals mecha-
nistic heterogeneity. Diabetes 2014;63:2158–2171
29. Suzuki R, Shimodaira H. Pvclust: an R package for assessing the un-
certainty in hierarchical clustering. Bioinformatics 2006;22:1540–1542
30. Yaghootkar H, Lamina C, Scott RA, et al. Mendelian randomization studies
do not support a causal role for reduced circulating adiponectin levels in insulin
resistance and type 2 diabetes. Diabetes 2013;62:3589–3598
31. Rees MG, Raimondo A, Wang J, et al. Inheritance of rare functional GCKR
variants and their contribution to triglyceride levels in families. Hum Mol Genet.
30 May 2014 [Epub ahead of print]
32. Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the
Metabolic Syndrome–an allostatic perspective. Biochim Biophys Acta 2010;1801:
338–349
33. Barak Y, Nelson MC, Ong ES, et al. PPAR gamma is required for placental,
cardiac, and adipose tissue development. Mol Cell 1999;4:585–595
34. Medina-Gomez G, Gray SL, Yetukuri L, et al. PPAR gamma 2 prevents
lipotoxicity by controlling adipose tissue expandability and peripheral lipid me-
tabolism. PLoS Genet 2007;3:e64
35. Barroso I, Gurnell M, Crowley VE, et al. Dominant negative mutations in
human PPARgamma associated with severe insulin resistance, diabetes mellitus
and hypertension. Nature 1999;402:880–883
diabetes.diabetesjournals.org Yaghootkar and Associates 4377
